BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas
- PMID: 37437144
- PMCID: PMC10464854
- DOI: 10.1056/NEJMoa2213329
BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas
Abstract
Background: Craniopharyngiomas, primary brain tumors of the pituitary-hypothalamic axis, can cause clinically significant sequelae. Treatment with the use of surgery, radiation, or both is often associated with substantial morbidity related to vision loss, neuroendocrine dysfunction, and memory loss. Genotyping has shown that more than 90% of papillary craniopharyngiomas carry BRAF V600E mutations, but data are lacking with regard to the safety and efficacy of BRAF-MEK inhibition in patients with papillary craniopharyngiomas who have not undergone previous radiation therapy.
Methods: Eligible patients who had papillary craniopharyngiomas that tested positive for BRAF mutations, had not undergone radiation therapy previously, and had measurable disease received the BRAF-MEK inhibitor combination vemurafenib-cobimetinib in 28-day cycles. The primary end point of this single-group, phase 2 study was objective response at 4 months as determined with the use of centrally determined volumetric data.
Results: Of the 16 patients in the study, 15 (94%; 95% confidence interval [CI], 70 to 100) had a durable objective partial response or better to therapy. The median reduction in the volume of the tumor was 91% (range, 68 to 99). The median follow-up was 22 months (95% CI, 19 to 30) and the median number of treatment cycles was 8. Progression-free survival was 87% (95% CI, 57 to 98) at 12 months and 58% (95% CI, 10 to 89) at 24 months. Three patients had disease progression during follow-up after therapy had been discontinued; none have died. The sole patient who did not have a response stopped treatment after 8 days owing to toxic effects. Grade 3 adverse events that were at least possibly related to treatment occurred in 12 patients, including rash in 6 patients. In 2 patients, grade 4 adverse events (hyperglycemia in 1 patient and increased creatine kinase levels in 1 patient) were reported; 3 patients discontinued treatment owing to adverse events.
Conclusions: In this small, single-group study involving patients with papillary craniopharyngiomas, 15 of 16 patients had a partial response or better to the BRAF-MEK inhibitor combination vemurafenib-cobimetinib. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT03224767.).
Copyright © 2023 Massachusetts Medical Society.
Figures


Comment in
-
BRAF-MEK Inhibition Is Effective in BRAFV600E-Mutant Papillary Craniopharyngioma.Cancer Discov. 2023 Sep 6;13(9):1960. doi: 10.1158/2159-8290.CD-RW2023-116. Cancer Discov. 2023. PMID: 37477404
References
-
- Karavitaki N, Brufani C, Warner JT, et al. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol (Oxf) 2005;62:397–409. - PubMed
-
- Greenfield BJ, Okcu MF, Baxter PA, et al. Long-term disease control and toxicity outcomes following surgery and intensity modulated radiation therapy (IMRT) in pediatric craniopharyngioma. Radiother Oncol 2015;114:224–9. - PubMed
-
- Duff J, Meyer FB, Ilstrup DM, Laws ER Jr, Schleck CD, Scheithauer BW. Long-term outcomes for surgically resected craniopharyngiomas. Neurosurgery 2000;46:291–302. - PubMed
-
- Liubinas SV, Munshey AS, Kaye AH. Management of recurrent craniopharyngioma. J Clin Neurosci 2011;18:451–7. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- UG1 CA233331/CA/NCI NIH HHS/United States
- UG1 CA233320/CA/NCI NIH HHS/United States
- UG1 CA233178/CA/NCI NIH HHS/United States
- UG1 CA233180/CA/NCI NIH HHS/United States
- U10 CA180882/CA/NCI NIH HHS/United States
- U24 CA196171/CA/NCI NIH HHS/United States
- UG1 CA189824/CA/NCI NIH HHS/United States
- U24 CA180803/CA/NCI NIH HHS/United States
- U10CA180821, U10CA180882, U24CA196171/CA/NCI NIH HHS/United States
- UG1 CA233339/CA/NCI NIH HHS/United States
- U10 CA180868/CA/NCI NIH HHS/United States
- UG1CA233331, UG1CA233339, UG1CA189824/CA/NCI NIH HHS/United States
- U10 CA180821/CA/NCI NIH HHS/United States
- UG1CA232760, UG1CA233178, UG1CA233180, UG1CA23332/CA/NCI NIH HHS/United States
- UG1 CA232760/CA/NCI NIH HHS/United States
- U10CA180868/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials